TrialCancer science2021

Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.

Yoshitaka Narita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.